Active — Not RecruitingPhase 2

First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients

Azerbaijan200 participantsStarted 2014-05

Plain-language summary

The goal of the study is to investigate of the prognostics and predictive role of TUBB3 expression in locally advanced breast cancer

Age range18 Years – 70 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: IIIC stage breast cancer patients Exclusion Criteria: Other stages breast cancer patients

Clinical tumor regression rate

Timeframe: 4 months

NCT IDNCT06531447

SponsorThe National Center of Oncology, Azerbaijan

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2017-11